2. Search Result
Search Result
Isoforms Recommended: Bim
Results for "

BIM

" in MedChemExpress (MCE) Product Catalog:

33

Inhibitors & Agonists

22

Peptides

1

Isotope-Labeled Compounds

1

Antibodies

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P3124A
    BIM-23190 hydrochloride

    		Somatostatin Receptor Cancer
    BIM-23190 hydrochloride, a somatostatin analog, a selective SSRT2 and SSRT5 agonist, exhibits Ki values of 0.34 nM and 11.1 nM for SSTR2 and SSTR5, respectively. BIM-23190 can be used in the study for cancer and acromegaly .
    <em>BIM</em>-23190 hydrochloride
  • HY-115930
    Bim-IN-1

    		Bcl-2 Family Cardiovascular Disease
    Bim-IN-1 is a potent Bim expression inhibitor. Bim-IN-1 reduces Bim expression levels and has little inhibitory effect upon protein kinase A activity and minimal toxicity .
    <em>Bim</em>-IN-1
  • HY-P2028
    BIM 21009

    		GnRH Receptor Cancer
    BIM 21009 is a LHRH and GnRH receptor antagonist. BIM 21009 inhibits tumor growth .
    <em>BIM</em> 21009
  • HY-P0039
    BIM-26226

    		Bombesin Receptor Cancer
    BIM-26226, gastrin-releasing peptide, is a potent and selective antagonist of bombesin receptor. BIM-26226 inhibits BN- or GRP-stimulated amylase release with IC50s in the nanomolar range. BIM-26226 can be used for the research of cancer .
    <em>BIM</em>-26226
  • HY-P3124
    BIM-23190

    		Somatostatin Receptor Cancer
    BIM-23190, a somatostatin analog, a selective SSTR2 and SSTR5 agonist, exhibits Ki values of 0.34 nM and 11.1 nM for SSTR2 and SSTR5, respectively. BIM-23190 can be used in the study for cancer and acromegaly .
    <em>BIM</em>-23190
  • HY-103277
    BIM 23042

    		Bombesin Receptor Neurological Disease Metabolic Disease
    BIM 23042, a certain somatostatin (SS) octapeptide analogue, is a selective neuropeptide neuromedin B receptor (NMB-R, BB1) antagonist. BIM 23042 has 100-fold lower affinity for gastrin-releasing peptide (GRP) receptor (BB2). BIM 23042 inhibits Neuromedin B (HY-P0241), ICI 216140 and DPDM-bombesin ethylamide-induced Ca 2+ release .
    <em>BIM</em> 23042
  • HY-103277A
    BIM 23042 TFA

    		Bombesin Receptor Neurological Disease Metabolic Disease
    BIM 23042 TFA, a certain somatostatin (SS) octapeptide analogue, is a selective neuropeptide neuromedin B receptor (NMB-R, BB1) antagonist. BIM 23042 has 100-fold lower affinity for gastrin-releasing peptide (GRP) receptor (BB2). BIM 23042 inhibits Neuromedin B (HY-P0241), ICI 216140 and DPDM-bombesin ethylamide-induced Ca 2+ release .
    <em>BIM</em> 23042 TFA
  • HY-10499
    PH-064
    1 Publications Verification

    BIM-46187

    		 Others Neurological Disease
    PH-064 (BIM-46187) is an inhibitor of heterotrimeric G-protein complex.
    PH-064
  • HY-119971
    BIM5078

    		Others Metabolic Disease Cancer
    BIM5078 is a hepatocyte nuclear factor 4α (HNF4α) antagonist that can inhibit the expression of known HNF4α target genes. BIM5078 represses insulin promoter activity through HNF4α antagonism. BIM5078 can be used for the research of cancer and diabetes .
    <em>BIM</em>5078
  • HY-P1527
    Bim BH3

    		Bcl-2 Family Others
    Bim BH3 is a biological active peptide. (This Bim peptide belongs to the pro-apoptotic Bcl-2 family of proteins.)
    <em>Bim</em> BH3
  • HY-P1889
    Bim BH3, Peptide IV

    		Bcl-2 Family Inflammation/Immunology
    Bim BH3, Peptide IV is a 26-residue peptide from BH3-only protein Bim, which belongs to the pro-apoptotic group of the Bcl-2 family of proteins .
    <em>Bim</em> BH3, Peptide IV
  • HY-P1203
    BIM-23056

    		Somatostatin Receptor Neurological Disease
    BIM 23056, a linear octapeptide, is a potent sst3 and sst5 somatostatin receptor antagonist with Ki values of 10.8, 5.7, respectively .
    <em>BIM</em>-23056
  • HY-P1889A
    Bim BH3, Peptide IV TFA

    		Bcl-2 Family Inflammation/Immunology
    Bim BH3, Peptide IV TFA is a 26-residue peptide from BH3-only protein Bim, which belongs to the pro-apoptotic group of the Bcl-2 family of proteins .
    <em>Bim</em> BH3, Peptide IV TFA
  • HY-P1203A
    BIM-23056 TFA

    		Somatostatin Receptor Neurological Disease
    BIM 23056 TFA, a linear octapeptide, is a potent sst3 and sst5 somatostatin receptor antagonist with Ki values of 10.8, 5.7, respectively .
    <em>BIM</em>-23056 TFA
  • HY-P3294
    Onzigolide

    BIM-23A760; TBR-760

    		 Dopamine Receptor Somatostatin Receptor Neurological Disease Cancer
    Onzigolide (BIM-23A760), a chimeric dopamine-somatostatin compound, shows potent agonist activity at both DA type 2 (D2R) and SST type 2 (SSTR2) receptors .
    Onzigolide
  • HY-108136A
    Bisindolylmaleimide X hydrochloride
    2 Publications Verification

    BIM-X hydrochloride; Ro31-8425 hydrochloride

    		 PKC CDK Cardiovascular Disease
    Bisindolylmaleimide X hydrochloride (BIM-X hydrochloride) is a potent and selective protein kinase C (PKC) inhibitor. Bisindolylmaleimide X hydrochloride is a potent cyclin-dependent kinase 2 (CDK2) antagonist with an IC50 of 200 nM .
    Bisindolylmaleimide X hydrochloride
  • HY-108742
    Abaloparatide
    1 Publications Verification

    BA 058; BIM 44058

    		 Thyroid Hormone Receptor Arrestin Metabolic Disease
    Abaloparatide (BA 058) is a parathyroid hormone receptor 1 (PTHR1) analog. Abaloparatide also is a selective PTHR1 activator. Abaloparatide enhances Gs/cAMP signaling and β-arrestin recruitment. Abaloparatide enhances bone formation and cortical structure in mice. Abaloparatide has the potential for the research of osteoporosis .
    Abaloparatide
  • HY-108742A
    Abaloparatide TFA
    1 Publications Verification

    BA 058 TFA; BIM 44058 TFA

    		 Thyroid Hormone Receptor Arrestin Metabolic Disease Endocrinology
    Abaloparatide TFA (BA 058 TFA) is a parathyroid hormone receptor 1 (PTHR1) analogue. Abaloparatide TFA also is a selective PTHR1 activator. Abaloparatide TFA enhances Gs/cAMP signaling and β-arrestin recruitment. Abaloparatide TFA enhances bone formation and cortical structure in mice. Abaloparatide TFA has the potential for the research of osteoporosis .
    Abaloparatide TFA
  • HY-112400
    Bisindolylmaleimide V

    BIM V

    		 Ribosomal S6 Kinase (RSK) Cancer
    Bisindolylmaleimide V is a cell-permeable negative control for protein kinase C inhibition studies with an IC50 value over 100 µM . Bisindolylmaleimide V blocks the activation of mitogen-stimulated protein kinase p70 s6k/p85 s6k (S6K) in vivo with an IC50 of 8 µM .
    Bisindolylmaleimide V
  • HY-19884A
    Relamorelin acetate

    RM-131 acetate; BIM-28131 acetate

    		 GHSR Metabolic Disease
    Relamorelin (RM-131) acetate, a pentapeptide ghrelin analog, is a selective ghrelin/growth hormone secretagogue receptor (GHSR) agonist with a Ki of 0.42 nM for GHS-1a receptor. Relamorelin acetate is centrally penetrant. Relamorelin acetate increases growth hormone levels and accelerates gastric emptying. Relamorelin acetate has the potential for cachexia, gastroparesis, and gastric/intestinal dysmobility disorders research .
    Relamorelin acetate
  • HY-19884
    Relamorelin

    RM-131; BIM-28131
    Relamorelin (RM-131), a pentapeptide ghrelin analog, is a selective ghrelin/growth hormone secretagogue receptor (GHSR) agonist with a Ki of 0.42 nM for GHS-1a receptor. Relamorelin is centrally penetrant. Relamorelin increases growth hormone levels and accelerates gastric emptying. Relamorelin has the potential for cachexia, gastroparesis, and gastric/intestinal dysmobility disorders research .
    Relamorelin
  • HY-P0165
    Taspoglutide

    ITM077; R1583; BIM51077

    		 GCGR Metabolic Disease
    Taspoglutide is a long-acting glucagon-like peptide 1 (GLP-1) receptor agonist developed for treatment of type 2 diabetes, with an EC50 value of 0.06 nM.
    Taspoglutide
  • HY-19884B
    Relamorelin TFA

    RM-131 TFA; BIM-28131 TFA

    		 GHSR Metabolic Disease
    Relamorelin (RM-131) TFA, a pentapeptide ghrelin analog, is a selective ghrelin/growth hormone secretagogue receptor (GHSR) agonist with a Ki of 0.42 nM for GHS-1a receptor. Relamorelin TFA is centrally penetrant. Relamorelin TFA increases growth hormone levels and accelerates gastric emptying. Relamorelin TFA has the potential for cachexia, gastroparesis, and gastric/intestinal dysmobility disorders research .
    Relamorelin TFA
  • HY-114989
    Fluorizoline
    1 Publications Verification

    		 Apoptosis Cancer
    Fluorizoline selectively and directly binds to prohibitin 1 (PHB1) and 2 (PHB2), and induces apoptosis. Fluorizoline reduces chronic lymphocytic leukemia (CLL) cell viability through the upregulation of NOXA and BIM. Fluorizoline exerts antitumor action in a p53-independent manner .
    Fluorizoline
  • HY-50907
    ABT-737
    Maximum Cited Publications
    36 Publications Verification

    		 Bcl-2 Family Apoptosis Autophagy Mitophagy Cancer
    ABT-737, a BH3 mimetic, is a potent Bcl-2, Bcl-xL and Bcl-w inhibitor with EC50s of 30.3 nM, 78.7 nM, and 197.8 nM, respectively. ABT-737 induces the disruption of the BCL-2/BAX complex and BAK-dependent but BIM-independent activation of the intrinsic apoptotic pathway. ABT-737 induces autophagy and has the potential for acute myeloid leukemia (AML) research .
    ABT-737
  • HY-101778
    ML311

    		Bcl-2 Family Cancer
    ML311 is a potent and selective inhibitor of the Mcl-1/Bim interaction.
    ML311
  • HY-162008
    S1g-10

    		HSP Bcl-2 Family Cancer
    S1g-10 is a Hsp70/Bim inhibitor, and shows antitumor activity in chronic myeloid leukemia cells .
    S1g-10
  • HY-161274
    Bfl-1-IN-1

    		Bcl-2 Family Cancer
    Bfl-1-IN-1 (Compound 15) is a potent and selective Bfl-1 inhibitor. Bfl-1-IN-1 inhibits Bfl-1 and Mcl-1 with Kis of 0.63 and 6.77 μM, respectively .
    Bfl-1-IN-1
  • HY-15191
    Sabutoclax

    BI-97C1

    		 Bcl-2 Family Cancer
    Sabutoclax is a potent and effective Bcl-2 Family (Bcl-2, Bcl-XL, Mcl-1, Bfl-1) inhibitor with IC50s of 0.32 μM, 0.31 μM, 0.20 μM, and 0.62 μM, respectively. Sabutoclax increases Bax, Bim, PUMA and survivin expression .
    Sabutoclax
  • HY-50868
    Bafetinib
    5+ Cited Publications

    INNO-406; NS-187

    		 Bcr-Abl Src Apoptosis Cancer
    Bafetinib is an orally active Lyn/Bcr-Abl tyrosine kinase inhibitor. Bafetinib enhances the activity of several pro-apoptotic Bcl-2 homology (BH) 3-pure proteins (Bim, Bad, Bmf, and Bik) through intrinsic apoptotic pathways regulated by the Bcl-2 family, and induces apoptosis of Ph + leukemia cells. Bafetinib has antitumor activity .
    Bafetinib
  • HY-121337
    Flurochloridone

    R-40244

    		 Apoptosis Bcl-2 Family Others
    Flurochloridone (R-40244) is a selective preemergence and persistent herbicide. Flurochloridone induces endoplasmic reticulum (ER) stress and activated unfolded protein response (UPR) signaling pathways. Flurochloridone impairs cell viability and induces cytotoxicity and apoptosis mediated by ER stress via activating eIF2α-ATF4/ATF6-CHOP-Bim/Bax signaling pathways in TM4 cells .
    Flurochloridone
  • HY-118948
    MSN-50

    		Bcl-2 Family Neurological Disease
    MSN-50 is a Bax and Bak oligomerization inhibitor. MSN-50 efficiently inhibits liposome permeabilization, prevents genotoxic cell death and promotes neuroprotection .
    MSN-50
  • HY-50907S
    ABT-737-d8

    		Biochemical Assay Reagents Cancer
    ABT 737-d8 is the deuterium labeled ABT-737. ABT-737, a BH3 mimetic, is a potent Bcl-2, Bcl-xL and Bcl-w inhibitor with EC50s of 30.3 nM, 78.7 nM, and 197.8 nM, respectively. ABT-737 induces the disruption of the BCL-2/BAX complex and BAK-dependent but BIM-independent activation of the intrinsic apoptotic pathway. ABT-737 induces autophagy and has the potential for acute myeloid leukemia (AML) research .
    ABT-737-d8

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: